ASeq Newsletter
Olink is developing a novel sequencing based proteomics platform. Their 2020 revenue was $54.1 million, 16.7% growth on 2019. This year growth looks set to be higher (in the 50% range). Interestingly the majority of their business seems to be service related
CommentShare
NewTopWhat is ASeq Newsletter?About
So Illumina are pushing forward with their GRAIL acquisition. It seems like a good time to review what (little) I know of the early stage cancer detect…
CommentShare
I was recently asked about Nooma Bio. This is a company and approach I’ve not looked at for some time. But it appears they published a couple of papers…
CommentShare
Solexa has come up in a few conversations recently. Obviously Solexa’s contribution to next-gen sequencing is difficult to ignore. But it’s also an int…
CommentShare
So it seems Twinstrand are suing Guardant over use of their duplex sequencing approach. This suggests that Guardant’s digital sequencing and Twinstrand…
CommentShare
Cees Dekker’s group recently published progress toward nanopore protein sequencing. The work addresses one of the fundamental issues in nanopore protei…
CommentShare
PacBio appear to be set to acquire Omniome for $600 million with an additional $200 million in milestone payments. Similar to Illumina’s proposed acqui…
CommentShare
Company Seer is a Proteomics sample prep company. They IPO’d earlier this year. Prior to that they appear to have raised $169.5M. Having been founded i…
CommentShare
See all

ASeq Newsletter


What is ASeq Newsletter?ArchiveAuthorsMy Account
© 2021 Nava Whiteford. See privacy, terms and information collection notice
Publish on Substack
ASeq Newsletter is on Substack – the place for independent writing